ArticleMedicine2026
Neutrophil percentage-to-albumin ratio and all-cause mortality in cancer survivors with cardiovascular disease: Evidence from NHANES 1999-2018.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neutrophil percentage-to-albumin ratio (NPAR) reflects both systemic inflammation and nutritional status, 2 factors closely linked to cancer progression and cardiovascular disease (CVD). While NPAR has been associated with adverse outcomes in various populations, its prognostic value in cancer survivors with comorbid CVD remains unclear. This study aimed to evaluate the association between NPAR and all-cause mortality in this high-risk population using nationally representative US data. We conducted a retrospective cohort study using data from the US National Health and Nutrition Examination Survey (NHANES, 1999-2018). A total of 1101 adult patients with both cancer and CVD were included. NPAR was evaluated as the exposure variable, and all-cause mortality was the outcome. Participants were categorized into tertiles according to NPAR. Kaplan-Meier survival curves were used to compare mortality across groups, and Cox proportional hazards regression models were applied to assess the independent association between NPAR and mortality risk. During a median follow-up of 77.9 months, higher NPAR levels were significantly associated with increased all-cause mortality. Kaplan-Meier analysis demonstrated significant differences in survival among tertiles (P < .0001). The median survival times were 73.0 months (IQR: 41.0-127.0), 70.0 months (IQR: 36.0-116.0), and 53.0 months (IQR: 26.8-102.0) for the lowest, middle, and highest tertiles, respectively. Multivariable Cox regression analysis confirmed that participants in the highest tertile had a significantly increased mortality risk compared with those in the middle tertile (HR = 1.54, 95% CI: 1.24-1.90, P < .001). Elevated NPAR is independently associated with higher all-cause mortality in adult cancer survivors with comorbid CVD. As a simple and readily available biomarker, NPAR may serve as a useful tool for early risk stratification and individualized management in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.